Panacea Bio Chem · HDAP2
References — every claim traced
Everything stated on hdap2.com comes from these primary sources. Where the record ends, we say nothing.
The primary paper
MacNeil MA, Arain S, Mentor W, Garcia-Marin V, Birk A. "The mitochondria-targeted peptide HDAP2 reduces mitochondrial loss and retinal ganglion cell degeneration after optic nerve injury." Neuroscience 598:187–199, 27 March 2026 (Epub 1 February 2026).
· PubMed record — PMID 41633465
· Free full text — PMC13080697
· DOI 10.1016/j.neuroscience.2026.01.045
The source of: the sequence (Biotin-dArg-Phe-Phe-dArg-amide), the design intent (support mitochondrial membrane integrity under cellular stress), the blood-retinal-barrier penetration, the RGC-survival and mitochondrial-density results (incl. the near-threefold figure), the prevention-not-rescue finding, and the authors' conclusion on CNS projection-neuron protection.
Authorship and intellectual property
Designers: MacNeil, Arain, Mentor, Garcia-Marin, Birk — Department of Biology, York College (CUNY) and the CUNY Graduate Center, New York. Synthesis for the study: GenScript (Piscataway, NJ). Patent on HDAP2 therapeutic applications: The Research Foundation, CUNY (inventors MacNeil and Birk) — the authors' competing interest declaration states no commercial relationships related to HDAP2 at publication.
Panacea Bio Chem investigates HDAP2 and claims no invention. Nothing here is medical advice.
Class context
The aromatic-cationic mitochondria-targeted peptide lineage HDAP2 belongs to is represented in the indexed literature by the elamipretide (SS31/MTP-131) family — cell-penetrating, mitochondria-localizing tetrapeptides. We name the class for orientation only; class behaviour is not evidence for HDAP2, which is why the study above is the only cited proof on this site.
Published 2026-08-23 · last evidence check 2026-08-23 · editorial policy.